Maseno Institutional Repository (IR) is a digital service that collects, preserves, and distributes digital material. Repositories are important tools for preserving an organization's legacy; they facilitate digital preservation and scholarly communication.

Communities in Maseno IR

Recently Added

  • Costs of continuing RTS, S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries 

    Ranju Baral, Ann Levin, Chris Odero, Clint Pecenka, Collins Tabu, Evans Mwendo, George Bonsu, John Bawa, John Frederick Dadzie, Joyce Charo, Kwadwo Odei Antwi-Agyei, Kwame Amponsa-Achianou, Rose Eddah Jalango, Rouden Mkisi, Scott Gordon, Temwa Mzengeza, Winthrop Morgan, Farzana Muhib (Public Library of Science, 2021-01-11)
    The RTS,S/ASO1E malaria vaccine is being piloted in three countries—Ghana, Kenya, and Malawi—as part of a coordinated evaluation led by the World Health Organization, with support from global partners. This study estimates ...

  • Correction: Costs of continuing RTS, S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries 

    Ranju Baral, Ann Levin, Chris Odero, Clint Pecenka, Collins Tabu, Evans Mwendo, George Bonsu, John Bawa, John Frederick Dadzie, Joyce Charo, Kwadwo Odei Antwi-Agyei, Kwame Amponsa-Achianou, Rose Eddah Jalango, Rouden Mkisi, Scott Gordon, Temwa Mzengeza, Winthrop Morgan, Farzana Muhib (Public Library of Science, 2021-04-22)
    Cost estimates under additional vaccine price assumptions are not included in the main result Table (Table 3). Please view S4 Table,“Unit cost of continuing to vaccinate in pilot areas at various vaccine prices,” for results ...

  • National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study 

    Jessica Price, Jessica Mooney, Carolyn Bain, John Tanko Bawa, Nikki Gurley, Amresh Kumar, Guwani Liyanage, Rouden Esau Mkisi, Chris Odero, Karim Seck, Evan Simpson, William P Hausdorff (Elsevier, 2022-01-21)
    Currently available live, oral rotavirus vaccines (LORVs) have significantly reduced severe rotavirus hospitalizations and deaths worldwide. However, LORVs are not as effective in low- and middle-income countries (LMIC) ...

  • Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries 

    Jessica Mooney, Jessica Price, Carolyn Bain, John Tanko Bawa, Nikki Gurley, Amresh Kumar, Guwani Liyanage, Rouden Esau Mkisi, Chris Odero, Karim Seck, Evan Simpson, William P Hausdorff (Public Library of Science, 2022-06-23)
    Live oral rotavirus vaccines (LORVs) have significantly reduced rotavirus hospitalizations and deaths worldwide. However, LORVs are less effective in low- and middle-income countries (LMICs). Next-generation rotavirus ...

  • Safety profile of the RTS, S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa 

    Yolanda Guerra Mendoza, Elodie Garric, Amanda Leach, Marc Lievens, Opokua Ofori-Anyinam, Jean-Yves Pirçon, Jens-Ulrich Stegmann, Pascale Vandoolaeghe, Lucas Otieno, Walter Otieno, Seth Owusu-Agyei, Jahit Sacarlal, Nahya Salim Masoud, Hermann Sorgho, Marcel Tanner, Halidou Tinto, Innocent Valea, Ali Takadir Mtoro, Patricia Njuguna, Martina Oneko, Godfrey Allan Otieno, Kephas Otieno, Samwel Gesase, Mary J Hamel, Irving Hoffman, Seyram Kaali, Portia Kamthunzi, Peter Kremsner, Miguel Lanaspa, Bertrand Lell, John Lusingu, Anangisye Malabeja, Pedro Aide, Pauline Akoo, Daniel Ansong, Kwaku Poku Asante, James A Berkley, Samuel Adjei, Tsiri Agbenyega, Selidji Todagbe Agnandji, Lode Schuerman (Taylor & Francis, 2019-10-03)
    A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in-depth safety results from this study. 8922 children ...

View more